Sciton Celebrates diVa Vaginal Laser Birthday

PALO ALTO, Calif., Feb. 8, 2018 /PRNewswire/ -- This month, Sciton, Inc., a leading manufacturer of medical and aesthetic lasers and light source devices, celebrates a 2-year milestone from establishing their Women's Health Group and product launch of their diVa Hybrid Fractional Laser on the flagship, Joule platform. Sciton has distinguished itself from competitors and gained market share with its unique, automated hybrid laser technology in an industry that traditionally has been dominated by single wavelength systems with manual devices. To date, upward of 10,000 diVa hybrid laser procedures have been performed.

Physicians who specialize in women's feminine health worldwide respond favorably to the diVa results-oriented solution meeting the growing and largely unmet demand of top concerns of women: post pregnancy laxity, atrophic issues with menopause and cancer therapy, stress incontinence, and sexual dysfunction. To understand the scope of this emerging market, The Medical Industry Report (April 2017) stated that global non-surgical Feminine Revitalization technology sales in 2016 was over $100 million with a rise expected of 26% through 2021. Physician fees for this period to 2021 will reach $2 billion.

"We have positioned our diVa and Joule platform to enable our customers to benefit from its versatile clinical offerings in women's health. Our diVa journey started by designing a next generation, hybrid laser with independent tunable wavelength control, complemented by our expandable modules that would improve the outcome and experience of the patient and the practitioner," states Kathy Ziegler, diVa Product and Education Manager. To that point, ongoing IRB driven clinical research was paramount in the framework of reaching success benchmarks. Another strategic move was the establishment of the Practice Development Partner Program. A team of marketing specialists focused on each customer's success by targeting and implementing proven marketing initiatives bringing about sustainable growth and continued flow of satisfied patients. This program goes beyond any of the competitors marketing support offerings in the vaginal health space.

"It is gratifying to me knowing that my being a key influencer in the development of diVa and the very first to perform it almost three years ago has benefited women worldwide," says Johnny Peet, MD, OB/GYN, Woodlands, TX. "In my practice, I have treated hundreds of women with success and remain dedicated to the advancements through IRB clinical research as well as future technology advancements."

In celebration of embarking on its third year, Sciton's Women's Health Group is hosting a collaborative meeting with its Clinical Review Board members at its headquarters in Palo Alto, CA later this month. This group acts as an advisory board of experts in laser and women's health and serves in the advancement of solution based medicine. The two-day Summit will be centered around new developments in clinical research, research and development for advanced technologies, a snapshot into the future and advanced training. "I am pleased to be an integral member of the Clinical Review Board and look forward to attending the upcoming Summit to share ideas, learn new technologies, and collaborate with my esteemed colleagues," says Michael Kennelly, MD, Urologist, Carolinas HealthCare System, Charlotte, NC.

Throughout February, Sciton will be executing several promotional initiatives in support of the 2-year achievement milestone. Aside from the Clinical Review Board Summit, other milestone achievements include key partnerships. Sciton is celebrating its partnership with The Young Survival Coalition and exceeding its diVa sales donation goal of $25,000. Sciton recently announced the goal was exceeded and a $42,300 donation will be given to YSC, for breast cancer awareness. Sciton's sponsorship of Young Survival Coalition organization is also celebrated by attending the YSC Annual Summit that hosts breast cancer survivors from throughout the US. This relationship reflects Sciton's ongoing mission of improving the quality of women's feminine health and financially supporting programs that make a tangible difference.

Other milestones include key partnerships with group purchasing partners, where diVa is the premier choice of laser technology. Additionally to this program, the Centers of Excellence Program will receive recognition for extending and expanding meritorious service to communities throughout the US and Canada.

diVa expands the broad range of Sciton's JOULE(TM) platform capabilities to address a woman's most intimate challenges. diVa is the world's first hybrid fractional laser for Vaginal Therapy and Vaginal Restoration. diVa is the only device available that includes HPA (High Precision Automation) technology to ensure the safest and best treatment outcome for patients and predictability for the operator. Additionally, diVa's dual-wavelength hybrid technology and tunability allows operators to customize treatments based on a patient's age, symptoms, and desired results.

Sciton, Inc., located in Palo Alto, California, is a totally employee-owned medical device company established in 1997 by co-founders Jim Hobart, Ph.D., and Dan Negus, Ph.D. Sciton was established with a focus on long-term results and making both patients and physicians happy. Sciton offers superior medical devices to treat women's health conditions, vascular lesions, pigmentation, skin texture and tone, scars, body contouring, skin laxity and hair reduction. Sciton operates on a worldwide basis with direct sales forces in the United States, Canada, Japan, Australia and distributor partners in more than 45 countries. For more information, and a complete listing of Sciton systems, visit


View original content with multimedia:

SOURCE Sciton, Inc.